Mid-point Transverse Process to Pleura Block for Breast Cancer Surgery: A Randomized Controlled Trial
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT03713255 |
Recruitment Status :
Recruiting
First Posted : October 19, 2018
Last Update Posted : October 3, 2022
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Breast Cancer Acute Pain Anesthesia | Procedure: PVB group Procedure: MTP block group Procedure: Control Group | Not Applicable |
Study Type : | Interventional (Clinical Trial) |
Estimated Enrollment : | 150 participants |
Allocation: | Randomized |
Intervention Model: | Parallel Assignment |
Intervention Model Description: | Prospective, randomized, quadruple-blinded, three arm parallel group clinical trial. |
Masking: | Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor) |
Masking Description: | Quadruple (participant, care provider, investigator, outcomes assessor) |
Primary Purpose: | Treatment |
Official Title: | Analgesic Benefits of the Novel Mid-point Transverse Process to Pleura (MTP) Block for Ambulatory Breast Cancer Surgery: A Randomized Controlled Trial |
Actual Study Start Date : | January 1, 2020 |
Estimated Primary Completion Date : | December 31, 2023 |
Estimated Study Completion Date : | December 31, 2023 |

Arm | Intervention/treatment |
---|---|
Active Comparator: PVB group
paravertebral blocks with 0.5% ropivacaine and epinephrine 2.5 mcg/mL
|
Procedure: PVB group
Patients in this group will receive preoperative ultrasound-guided thoracic paravertebral block using ropivacaine 0.5% with epinephrine 2.5 mcg/mL, and supplemental standardized anesthetic/analgesic regimen (Acetaminophen / NSAIDs / opioids for breakthrough pain). |
Experimental: MTP block group
MTP blocks with 0.5% ropivacaine and epinephrine 2.5 mcg/mL
|
Procedure: MTP block group
Patients in this group will receive preoperative ultrasound-guided mid-point transverse process to pleura block using ropivacaine 0.5% with epinephrine 2.5 mcg/mL, and supplemental standardized anesthetic/analgesic regimen (Acetaminophen / NSAIDs / opioids for breakthrough pain). |
Sham Comparator: control group
local anesthetic infiltration subcutaneous 1% lidocaine
|
Procedure: Control Group
Patients in this group will receive preoperative ultrasound-guided sham block with subcutaneous local anesthetic injection using lidocaine 1%, and supplemental standardized anesthetic/analgesic regimen (Acetaminophen / NSAIDs / opioids for breakthrough pain). |
- Postoperative analgesia during the first 24 hours. [ Time Frame: 48 hours ]Measured by opioid (equivalents of morphine) consumption and pain scores on a numerical rating scale.
- Post-operative quality of recovery during the first 24 hours. [ Time Frame: 48 hours ]Measured by the Quality of recovery (QoR-15 scale).

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years to 65 Years (Adult, Older Adult) |
Sexes Eligible for Study: | Female |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- English or French Speaking
- Scheduled for major breast surgery
- ASA physical status classification I-III
- BMI <30kg/m2
Exclusion Criteria:
- Prior ipsilateral breast surgery
- Pre-existing neurological deficit or peripheral neuropathy involving the ipsilateral chest
- Contraindications to regional anesthesia
- Patient refusal of regional technique
- Chronic pain disorder
- Chronic opioid use
- Inability to provide informed consent

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03713255
Contact: Ioana Costache, MD | (613) 737-8187 | icostache@toh.ca |
Canada, Ontario | |
The Ottawa Hospital | Recruiting |
Ottawa, Ontario, Canada | |
Contact: Ioana Costache, MD |
Principal Investigator: | Ioana Costache, MD | Ottawa Hospital, Ottawa Hospital Research Institute |
Responsible Party: | Ottawa Hospital Research Institute |
ClinicalTrials.gov Identifier: | NCT03713255 |
Other Study ID Numbers: |
20180259-01H |
First Posted: | October 19, 2018 Key Record Dates |
Last Update Posted: | October 3, 2022 |
Last Verified: | September 2022 |
Studies a U.S. FDA-regulated Drug Product: | No |
Studies a U.S. FDA-regulated Device Product: | No |
Regional Anesthesia Paravertebral Block Breast Cancer Surgery MTP block |
Breast Neoplasms Acute Pain Neoplasms by Site Neoplasms |
Breast Diseases Skin Diseases Pain Neurologic Manifestations |